These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 26391972

  • 1. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J.
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A, Hatton GB, Merchant HA, Basit AW.
    Int J Pharm; 2015 Apr 30; 484(1-2):103-8. PubMed ID: 25721685
    [Abstract] [Full Text] [Related]

  • 3. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
    Andreas CJ, Tomaszewska I, Muenster U, van der Mey D, Mueck W, Dressman JB.
    Eur J Pharm Biopharm; 2016 Aug 30; 105():193-202. PubMed ID: 27322002
    [Abstract] [Full Text] [Related]

  • 4. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
    Abinusawa A, Tenjarla S.
    Adv Ther; 2015 May 30; 32(5):477-84. PubMed ID: 25951927
    [Abstract] [Full Text] [Related]

  • 5. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S, Kambayashi A, Kojima H, Oku N, Asai T.
    Biol Pharm Bull; 2018 May 30; 41(11):1708-1715. PubMed ID: 30381671
    [Abstract] [Full Text] [Related]

  • 6. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
    Schellekens RC, Stuurman FE, van der Weert FH, Kosterink JG, Frijlink HW.
    Eur J Pharm Sci; 2007 Jan 30; 30(1):15-20. PubMed ID: 17085024
    [Abstract] [Full Text] [Related]

  • 7. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ, Pepin X, Markopoulos C, Vertzoni M, Reppas C, Dressman JB.
    Eur J Pharm Sci; 2017 May 01; 102():284-298. PubMed ID: 28286289
    [Abstract] [Full Text] [Related]

  • 8. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):434-41. PubMed ID: 19491035
    [Abstract] [Full Text] [Related]

  • 9. Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV.
    Reppas C, Vrettos NN, Dressman J, Andreas CJ, Miyaji Y, Brown J, Etherson K, Hanley S, Karkossa F, Karlsson E, Klein S, Maier GM, McAllister M, Mistry N, Rosenblatt K, Schäfer KJ, Smith KL, Tomaszewska I, Williams J, Winge F, Vertzoni M.
    Eur J Pharm Biopharm; 2020 Nov 28; 156():40-49. PubMed ID: 32882421
    [Abstract] [Full Text] [Related]

  • 10. Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol.
    Fadda HM, Mohamed MA, Basit AW.
    Int J Pharm; 2008 Aug 06; 360(1-2):171-6. PubMed ID: 18547758
    [Abstract] [Full Text] [Related]

  • 11. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
    Karkossa F, Klein S.
    J Pharm Sci; 2018 Jun 06; 107(6):1680-1689. PubMed ID: 29499277
    [Abstract] [Full Text] [Related]

  • 12. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems.
    Fadda HM, Merchant HA, Arafat BT, Basit AW.
    Int J Pharm; 2009 Dec 01; 382(1-2):56-60. PubMed ID: 19666093
    [Abstract] [Full Text] [Related]

  • 13. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F, Holm P, Larsen F, Steffansen B.
    Int J Pharm; 2014 Jan 30; 461(1-2):419-26. PubMed ID: 24342711
    [Abstract] [Full Text] [Related]

  • 14. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M, Schneider F, Jedamzik P, Wiedmann M, Schremmer E, Koziolek M, Weitschies W.
    Mol Pharm; 2017 Dec 04; 14(12):4272-4280. PubMed ID: 29064257
    [Abstract] [Full Text] [Related]

  • 15. Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon.
    Nguyen C, Christensen JM, Ayres JW.
    Pharm Dev Technol; 2012 Dec 04; 17(1):73-83. PubMed ID: 20923254
    [Abstract] [Full Text] [Related]

  • 16. Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations.
    Koziolek M, Kostewicz E, Vertzoni M.
    AAPS PharmSciTech; 2018 Oct 04; 19(7):2885-2897. PubMed ID: 30155808
    [Abstract] [Full Text] [Related]

  • 17. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
    Schilderink R, Protopappa M, Fleth-James J, Vertzoni M, Schaefer K, Havenaar R, Kulla I, Metzger M, Reppas C.
    Eur J Pharm Biopharm; 2020 Apr 04; 149():154-162. PubMed ID: 32057905
    [Abstract] [Full Text] [Related]

  • 18. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.
    Tenjarla S.
    Drugs R D; 2015 Jun 04; 15(2):211-5. PubMed ID: 26115756
    [Abstract] [Full Text] [Related]

  • 19. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressman JB.
    Eur J Pharm Biopharm; 2010 Sep 04; 76(1):95-104. PubMed ID: 20576487
    [Abstract] [Full Text] [Related]

  • 20. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M, Somville P, Vertzoni M, Fotaki N.
    AAPS J; 2022 Jan 10; 24(1):26. PubMed ID: 35013835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.